Cardiovascular Toxicology

, 11:373

N-acetylcysteine Offers Cardioprotection by Decreasing Cardiac Lipid Hydroperoxides and 8-Isoprostane Level in Isoproterenol-Induced Cardiotoxicity in Rats

  • Nagaraja Haleagrahara
  • Varkkey Julian
  • Srikumar Chakravarthi
Article

Abstract

This study investigated the cardioprotective effect of N-acetylcysteine (NAC) on isoproterenol (ISO)-induced cardiotoxicity in rats. Male Sprague–Dawley rats were divided into control, NAC alone (100 mg/kg BW orally for 14 days), ISO-control (85 mg/kg BW), and ISO with NAC (for 14 days). Serum creatine kinase-MB and Lactate dehydrogenase were measured. From the heart homogenate lipid hydroperoxides (LPO), superoxide dismutase (SOD), total glutathione (GSH), and 8-isoprostane (IP) were measured. Histopathological examination of the heart was also carried out. There was a significant increase (P < 0.05) in LPO and IP levels in ISO-control group and NAC treatment reduced these changes. Antioxidant enzyme, SOD and GSH, level decreased significantly (P < 0.05) in ISO-control group, and treatment with NAC was able to reverse these changes significantly (P < 0.05). Histopathologically, ISO-control group showed morphological changes suggestive of cardiotoxicity with large areas of coagulative necrosis, with diffused interstitial edema. NAC treatment successfully reduced these histopathological changes. In conclusion, the study proves that NAC has a strong cardioprotective effect against isoproterenol-induced cardiac changes. NAC decreases isoproterenol-induced LPO and IP levels in the heart tissue and prevented free radicals–induced damage to the myocardium.

Keywords

Cardiotoxicity N-acetylcysteine Isoproterenol Lipid hydroperoxides Isoprostane 

References

  1. 1.
    Lopez, A. D., & Murrau, C. C. (1998). The global burden disease, 1990–2020. Nature Medicine, 4, 1241–1243.PubMedCrossRefGoogle Scholar
  2. 2.
    Towbin, J. A. (2001). Molecular genetic basis of sudden cardiac death. Cardiovascular Pathology, 10, 283–295.PubMedCrossRefGoogle Scholar
  3. 3.
    Smith, G. D., Shipley, M. J., Marmot, M. G., & Rose, G. (1992). Plasma cholesterol concentration and mortality. The Whitehall study. The Journal of the American Medical Association, 267, 70–76.CrossRefGoogle Scholar
  4. 4.
    Thygesen, K., Alpert, J. S., & White, H. D. (2007). Universal definition of myocardial infarction. Journal of American College of Cardiology, 50, 2173–2195.CrossRefGoogle Scholar
  5. 5.
    Choudhary, R., Mishra, K. P., & Subramanyam, C. (2006). Prevention of isoproterenol-induced cardiac hypertrophy by eugenol, an antioxidant. Indian Journal of Clinical Biochemistry, 21, 107–113.CrossRefGoogle Scholar
  6. 6.
    Libby, P. (2001). Current concepts of pathogenesis of the acute coronary syndromes. Circulation, 104, 365–372.PubMedGoogle Scholar
  7. 7.
    Lilly, L. S. (2006). Pathophysiology of heart disease: A collaborative project of medical students and faculty (4th ed., pp. 131–184). Baltimore, MD: Lippincott Williams & Wilkins.Google Scholar
  8. 8.
    Ferrari, R., Alfieri, O., Curello, S., Ceconi, C., Cargnoni, A., & Marzollo, P. (1990). Occurrence of oxidative stress during reperfusion of the human heart. Circulation, 81, 201–211.PubMedCrossRefGoogle Scholar
  9. 9.
    Lefer, D. J., & Grabger, D. N. (2000). Oxidative stress and cardiac disease. American Journal of Medicine, 109, 315–323.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhou, R., Xu, Q., Zheng, P., Yan, L., Zheng, J., & Dai, G. (2008). Cardioprotective effect of fluvastatin on isoproterenol-induced myocardial infarction in rat. European Journal of Pharmacology, 586, 244–250.PubMedCrossRefGoogle Scholar
  11. 11.
    Lawson, J. S., Rokach, J., & Fitzgerald, G. A. (1999). Isoprostanes: Formation, analysis and sue as indices of lipid peroxidation in vivo. The Journal of Biological Chemistry, 274, 24441–24444.PubMedCrossRefGoogle Scholar
  12. 12.
    Cracowski, J. L., Durand, T., & Bessard, G. (2002). Isoprostanes as a biomarker of lipid peroxidation in humans: Physiology, pharmacology, and clinical implications. Trends in Pharmacological Sciences, 23, 360–366.PubMedCrossRefGoogle Scholar
  13. 13.
    Morrow, J. D., & Roberts, L. J. (1996). The isoprostanes. Current knowledge and directions for future research. Biochemical Pharmacology, 51, 1–9.PubMedCrossRefGoogle Scholar
  14. 14.
    Rajadurai, M., Mainzen, S., & Prince, P. (2006). Preventive effect of naringin on lipids, lipoproteins and lipid metabolic enzymes in isoproterenol-induced myocardial infarction in Wistar rats. Journal of Biochemical and Molecular Toxicology, 20, 191–197.PubMedCrossRefGoogle Scholar
  15. 15.
    Rathore, N., John, S., Kale, M., & Bhatnagar, D. (1998). Lipid peroxidation and antioxidant enzymes in isoproterenol-induced oxidative stress in rat tissues. Pharmacological Research, 38, 297–303.PubMedCrossRefGoogle Scholar
  16. 16.
    Arstall, M. A., Yang, J., Stafford, I., Betts, H., & Horowitz, J. D. (1995). N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving myocardial infarction. Circulation, 92, 2855–2862.PubMedGoogle Scholar
  17. 17.
    Kerksick, C., & Willoughby, D. (2005). The antioxidant role of glutathione and N-acetylcysteine supplements and exercise-induced oxidative stress. The Journal of the International Society of Sports Nutrition, 2, 38–44.CrossRefGoogle Scholar
  18. 18.
    Keles, M. S., Demirci, N., Yildirim, A., Atamanalp, S. S., & Altinkaynak, K. (2008). Protective effects of N-acetylcysteine and Ginkgo biloba extract on ischaemia-reperfusion-induced hepatic DNA damage in rats. Clinical and Experimental Medicine, 8, 193–198.PubMedCrossRefGoogle Scholar
  19. 19.
    Banerjee, S. K., Sood, S., Dinda, A. K., Das, T. K., & Maulik, S. K. (2003). Chronic oral administration of raw garlic protects against isoproterenol-induced myocardial necrosis in rat. Comparative Biochemistry Physiology Toxicology Pharmacology, 136, 377–386.CrossRefGoogle Scholar
  20. 20.
    Krenek, P., Kmecova, J., Kucerova, D., Bajuszova, Z., Musil, P., & Gazova, A. (2009). Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function. European Journal of Heart Failure, 11, 140–146.PubMedCrossRefGoogle Scholar
  21. 21.
    Fozzard, H. A. (1975). Validity of myocardial infarction model. Circulation, 52, 131–146.Google Scholar
  22. 22.
    Panda, V. S., & Naik, S. R. (2008). Cardioprotective activity of Ginkgo biloba phytosomes in isoproterenol-induced myocardial necrosis in rats: A biochemical and histoarchitectural evaluation. Experimental and Toxicologic Pathology, 60, 397–404.PubMedCrossRefGoogle Scholar
  23. 23.
    Grimm, D., Elsner, D., Schunkert, H., Pfeifer, M., Griese, D., Bruckschlegel, G., et al. (1998). Development of heart failure following isoproterenol administration in the rat: Role of the renin-angiotensin system. Cardiovascular Research, 37, 91–100.PubMedCrossRefGoogle Scholar
  24. 24.
    Senthil, S., Sridevi, M., & Pugalendi, K. V. (2007). Cardioprotective effect of oleanolic acid on isoproterenol-induced myocardial ischemia in rats. Toxicologic Pathology, 35, 418–423.PubMedCrossRefGoogle Scholar
  25. 25.
    Liu, B., Li, W., Li, Y., Wang, Z., Li, H., Liu, P., et al. (2009). Protective effects of N-acetylcysteine in isoproterenol-induced myocardium injury in rats. Molecular Biology Reports, 36, 761–765.PubMedCrossRefGoogle Scholar
  26. 26.
    Nagoor Meeran, M. F., & Mainzen Prince, P. S. (2011). Protective effects of N-acetylcysteine on lipid peroxide metabolism on isoproterenol-induced myocardial infarcted rats. Journal of Biochemical and Molecular Toxicology, 25, 151–157.PubMedCrossRefGoogle Scholar
  27. 27.
    Pinelli, A., Trivulzio, S., Tomasoni, L., Brenna, S., Bonacina, E., & Accinni, R. (2004). Isoproterenol-induced myocardial infarction in rabbits Protection by propanolol or labetolol: A proposed non-invasive procedure. The European Journal of Pharmaceutical Sciences, 23, 277–285.Google Scholar
  28. 28.
    Wang, S. B., Tian, S., Yang, F., Yang, H. G., Yang, X. Y., & Du, G. H. (2009). Cardioprotective effect of salvianolic acid—A on isoproterenol-induced myocardial infarction in rats. European Journal of Pharmacology, 615, 125–132.PubMedCrossRefGoogle Scholar
  29. 29.
    Peer, P. A., Trivedi, P. C., Nigade, P. B., Ghaisas, M. M., & Deshpande, A. D. (2008). Cardioprotective effect of Azadirachta indica A. Juss. On isoprenaline induced myocardial infarction in rats. International Journal of Cardiology, 126, 123–126.PubMedCrossRefGoogle Scholar
  30. 30.
    Upaganlawar, A., Gandhi, C., & Balaraman, R. (2009). Effect of green tea and vitamin E combination in Isoproterenol-induced myocardial infarction in rats. Plant Foods and Human Nutrition, 64, 75–80.CrossRefGoogle Scholar
  31. 31.
    Wittstein, I. S., Thiermann, D. R., Lima, J. A. C., Baughman, K. L., Schulman, S. P., & Gerstenblith, G. (2005). Neurohumoral features of myocardial stunning due to sudden emotional stress. New England Journal of Medicine, 352, 539–548.PubMedCrossRefGoogle Scholar
  32. 32.
    Bolli, R., & Marbán, E. (1999). Molecular and cellular mechanisms of myocardial stunning. Physiological Reviews, 79, 609–634.PubMedGoogle Scholar
  33. 33.
    Dikshit, M., Van Oosten, M. H., de Graff, S., & Srimal, R. C. (1992). Free radical scavenger mechanisms in experimentally induced ischemia in the rabbit heart and protective effect of verapamil. Archives of International Pharmacodynamics Therapy, 318, 55–65.Google Scholar
  34. 34.
    Remiao, F., Carmo, H., Carcalho, F. D., & Bastos, M. L. (2000). Inhibition of glutathione reductase by isoproterenol-induced oxidation products. Journal of Enzyme Inhibition and Medicinal Chemistry, 15, 47–61.Google Scholar
  35. 35.
    Mathew, S., Menon, P. V. G., & Kurup, P. A. (1978). Changes in myocardial and aortic lipids, lipolytic activity and fecal excretion of sterols and bile acids in isoproterenol-induced myocardial infarction in rats. Indian Journal Biochemistry, 18, 131–133.Google Scholar
  36. 36.
    Bloom, S., & Davis, D. L. (1972). Calcium as mediator of isoproterenol-induced myocardial necrosis. American Journal of Pathology, 69, 459–470.PubMedGoogle Scholar
  37. 37.
    Boucher, M., Pesant, S., Lei, Y. H., Nanton, N., Most, P., & Eckhart, A. D. (2008). Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clinical and Translational Science, 1, 13–20.PubMedCrossRefGoogle Scholar
  38. 38.
    Montuschi, P., Ciabattoni, G., Paredi, P., du Bois, R. M., Pantelidis, P., Kharitonov, S. A., et al. (1998). 8-Isoprostane as a biomarker of oxidative stress in interstitial lung disease. American Journal Respiratory Critical Care Medicine, 158, 1524–1527.Google Scholar
  39. 39.
    Maier, C. M., & Chan, P. H. (2002). Book review: Role of superoxide dismutases in oxidative damage and neurodegenerative disorders, vol. 8, issue no. 4. Beverley Hills: Sage.Google Scholar
  40. 40.
    Bolli, R. (1990). Mechanism of myocardial stunning. Circulation, 82, 723–738.PubMedCrossRefGoogle Scholar
  41. 41.
    Dickey, D. T., Muldoon, L. L., Doolittle, N. D., Peterson, D. R., Kraemer, D. F., & Neuwelt, E. A. (2008). Effect of N-acetylcysteine route of administration on chemoprotection against cisplatin-induced toxicity in rat models. Cancer Chemotherapy and Pharmacology, 62, 235–241.PubMedCrossRefGoogle Scholar
  42. 42.
    Suke, S. G., Ahmed, R. S., Pathak, R., Tripathi, A. K., & Banerjee, B. D. (2008). Attenuation of phosphamidon-induced oxidative stress and immune dysfunction in rats treated with N-acetylcysteine. Brazilian Journal of Medicine Biology Research, 41, 765–768.Google Scholar
  43. 43.
    Nagoor Meeran, M. F., & Mainzen Prince, P. S. (2011). Protective effects of N-acetylcysteine on lipid peroxide metabolism on isoproterenol-induced myocardial infarcted rats. Journal of Biochemical and Molecular Toxicology, 25, 151–157.PubMedCrossRefGoogle Scholar
  44. 44.
    Basha, R. H., Priscilla, D. H. (2011). An in vivo and in vitro study on the protective effects of N-acetylcysteine on mitochondrial dysfunction in isoproterenol treated myocardial infarcted rats. Experimental and Toxicologic Pathology, 3 Jun 2011 [Epub ahead of print].Google Scholar
  45. 45.
    Decaro, L., Ghizzi, A., & Costa, R. (1989). Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneimittel Forchung, 39, 382–385.Google Scholar
  46. 46.
    Abe, M., Takiguchi, Y., Ichimaru, S., Tsuchiya, K., & Wada, K. (2008). Comparison of the protective effect of N-acetylcysteine by different treatments on rat myocardial ischemia-reperfusion injury. Journal of Pharmacological Sciences, 106, 571–577.PubMedCrossRefGoogle Scholar
  47. 47.
    Finkel, M. S., Shen, L., Oddis, C. V., Romeo, R. C., & Salama, G. (1993). Positive inotropic effect of acetylcysteine in cardiomyopathic Syrian hamsters. Journal of Cardiovascular Pharmacology, 21, 29–34.PubMedCrossRefGoogle Scholar
  48. 48.
    Zaidi, N. F., Lagenaur, C. F., Abramson, J. J., Pessah, I., & Salama, G. (1989). Reactive disulfides trigger Ca2+ release from sarcoplasmic reticulum via an oxidation reaction. Journal of Biological Chemistry, 264, 21725–21736.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Nagaraja Haleagrahara
    • 1
  • Varkkey Julian
    • 2
  • Srikumar Chakravarthi
    • 3
  1. 1.Human Biology Division, School of MedicineInternational Medical UniversityKuala LumpurMalaysia
  2. 2.Division of Postgraduate StudiesInternational Medical UniversityKuala LumpurMalaysia
  3. 3.Pathology Division, School of MedicineInternational Medical UniversityKuala LumpurMalaysia

Personalised recommendations